cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Bayu Brahma
Contact Email
journal.cancer@gmail.com
Phone
+628176389956
Journal Mail Official
admin@indonesianjournalofcancer.or.id
Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta
Location
Kota adm. jakarta barat,
Dki jakarta
INDONESIA
Indonesian Journal of Cancer
Published by National Cancer Center-Dharmais Cancer Hospital
ISSN : 19783744     EISSN : 23556811     DOI : https://www.doi.org/ 10.33371
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health
Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.
Arjuna Subject : Kedokteran - Onkologi
Articles 6 Documents
 1 
Search results for , issue "Vol 8, No 3 (2014): Jul - Sep 2014" : 6 Documents clear
Gambaran Status Metilasi Gen Promoter Methylguanine-deoksiribonucleic Acid Methyltransferase pada Astrositoma dan Faktor yang Memengaruhinya
Indonesian Journal of Cancer Vol 8, No 3 (2014): Jul - Sep 2014
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (50.759 KB) | DOI: 10.33371/ijoc.v8i3.355

Abstract

Astrocytoma is the most common primary central nervous system tumor with difficult management as it requires acombination of surgery, chemotherapy and radiotherapy. This multimodalities approach increases patients survivalrate significantly, however chemotherapy resistance is now commonly seen. One of the potential causes of chemotherapyresistance is the epigenetic factors from O6 methylguanine-DNA-methyltransferase (MGMT) gene. MGMT gene has arole in DNA repair and also have a protective effect against exogenous and endogenous alkylation agents. The methylationof MGMT gene promoter leads to the decrease of MGMT protein, attenuating its function. Therefore, the methylationstatus of MGMT gene promoter can act as an indicator for astrocytomas progressivity and treatment progressivity.The aim of this study to determine the frequency of MGMT gene promoter methylation among patients withastrocytomas using methylation specific polymerase chain reaction (MS-PCR) and methylation sensitive highresolution melting (MS-HRM).Clinical data, imaging and parafin blocks from astrocytoma patients were collected in RSCM from 2008-2012. Themethylation status of MGMT gene promoter was confirmed using MS-PCR and MS-HRM. This is cross-sectional study.The total of 13 samples collected including 7 low-grade and 6 high-grade astrocytomas. The MGMT gene promoter wasmethylated in 1/13 cases using MS-PCR and 4/13 cases using MS-HRM. All methylated cases were low-gradeastrocytoma. There was significant association between the methylation status of MGMT gene promoter with thedegree of malignancy which is 4/7 samples hypermethylated in low-grade with no hypermethylation in high-gradeastrocytomas (p=0.049). While other factors like age, sex, karnofsky performance scale (KPS) and astrocytomas locationhave no significant association (p= 1,000; p= 0,657; p= 0,354; p= 0,538).The present study showed difference of methylation of MGMT gene promoter in astrocytomas with others studies whichis hypermethylated MGMT only found in low grade astrocytomas. Our study was the first to report the frequency ofMGMT promoter methylation among Indonesian astrocytoma patients.
Peran Faktor Nutrisi pada Pencegahan Kanker Prostat NICHOLAS TAMBUNAN
Indonesian Journal of Cancer Vol 8, No 3 (2014): Jul - Sep 2014
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (854.476 KB) | DOI: 10.33371/ijoc.v8i3.358

Abstract

Prostate cancer is a malignancy disease which originates in prostate organ that only can be found in men. This cancer is the second most common in men after lung cancer and the fifth in the entire world. The incidence will be increasing in the fifth decade of life with the peak in the eight decade. Several factors which are thought to be the etiology are: genetic, hormonal, diet, environment, and infection. Diet factor has great influence for both, the development and the prevention of this disease. Man who consumes high fat diet will have not only the risk to get that disease but also will increase the progresiveness of the disease. Several nutrients that are thought for decreasing the incidence of the prostate cancer are cruciferous vegetables and fruits which contain carotenoid. Furthermore, soya which contains much of isoflavon or phytoestrogen can also acts as the prevention of development of cancer cell. Green tea, lycopene ( carotenoid group that can be found in tomato products) can also act as the source of the antioxidant. This paper will discuss the role of nutrition factors of lycopene and soya in prostate cancer.
Hubungan antara Ekspresi p63 dengan Jenis Histopatologis Penderita Kanker Serviks Stadium IB2 dan IIA
Indonesian Journal of Cancer Vol 8, No 3 (2014): Jul - Sep 2014
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (50.759 KB) | DOI: 10.33371/ijoc.v8i3.354

Abstract

HPV is known the main etiology of cervical cancer, through its E6 and E7 oncogenes that inactivate p53 and retinoblastoma protein, thus suggested as the mechanism of phenotype changes. As the p53 homologs was found, p73 and p63, study focusing on p53 is more complex. Analysis of p63 expression by immunohistochemistry has prognostic and predictive value on several tumor types. P63 has main role on stratified epithelial growth by maintaining proliferation and differentiation. This study was analytic observational with cross sectional design. All subjects underwent cervical biopsy and were analyzed for p63 expression by immunohistochemistry. Statistical analyze used in this study were chi square and Mann Whitney. This study has been approved by the institution ethical committee. We found no significant correlation between subjects characteristic (age, marital age, parity) and clinical stage of cervical cancer (p>0.05). Our samples consisted of 25 squamous cell carcinoma (64%), 11 adenocarcinoma (28%), and 3 adenosquamous carcinoma (8%). Expression of p63 had no correlation with clinical stage, however its nuclear expression was significantly higher on squamous carcinoma type (72%) compared to adenocarcinoma (11%), with p < 0.001. Conclusion: expression of p63 on squamous cell carcinoma cervix is significantly higher compared to adenocarcinoma or adenosquamous.
Korelasi Hypoxia Inducible Factor- 1A (HIF-1A) dan Vascular Endothelial Growth Factor (VEGF) Dengan Hasil Operasi pada Kanker Ovarium Jenis Epitel
Indonesian Journal of Cancer Vol 8, No 3 (2014): Jul - Sep 2014
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (50.759 KB) | DOI: 10.33371/ijoc.v8i3.351

Abstract

Hypoxia inducible factor 1? (HIF-1?) regulates gene involved inresponse to hypoxia and promotes angiogenesis. HIF-1? is atranscriptional factor to induce vascular endothelial growth factor(VEGF). The objective of this study was to examine the correlation ofHIF-1? and VEGF expression with surgical outcome in epithelialovarian cancer, therefore could predict optimality of debulking inovarian cancer.Thirty patients with epithelial ovarian cancer who underwent primarysurgery were included in this study. Tumor tissues were obtainedfrom surgery and examined with q reverse transcriptase polymerasechain reaction (qRT-PCR) for HIF-1? and VEGF expression analysis.Evaluation of surgical outcome was based on volume of residualtumor. Correlation between HIF-1? and VEGF was analyzed by usingSpearman correlation test while the correlation between HIF-1? andVEGF and surgical outcome was analyzed by ANOVA.Results: The mean age of the study subjects was 47.5310.41 years.Eleven patients (36.7%) were diagnosed with stage I ovarian cancer,9 patients (30%) with stage II, 8 patients (26.7%) stage III and 2patients (6.7%) with stage IV. Out of 30 patients, 22 patients (73.3%)successfully underwent optimal debulking and 8 patients (26.7%)with suboptimal debulking. There was a correlation between HIF-1?and VEGF expression (r=0.582) but no correlation between HIF-1?and VEGF expression with surgical outcome in patients withepithelial ovarian cancer.Conclusion: There was a significant correlation between HIF-1? andVEGF expression but no significant correlation between HIF-1? andVEGF expression with surgical outcomes.
Kesesuaian Sistem TIRADS Dengan Hasil Pemeriksaan Patologi Anatomi Nodul Tiroid
Indonesian Journal of Cancer Vol 8, No 3 (2014): Jul - Sep 2014
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (50.759 KB) | DOI: 10.33371/ijoc.v8i3.356

Abstract

Thyroid ultrasonography is the modality of choice to detect, and to evaluate the morphology of thyroid nodule. ThyroidImaging Reporting and Data System (TIRADS) is a system to evaluate risk of malignancy of thyroid nodule, that firstproposed by Horvath et al. There are various TIRADS proposed by other authors. To the author knowledge, until thewriting of this study there is not yet found a study to evaluate implementation and diagnostic value of TIRADS inIndonesian.Methods: Diagnostic study with cross sectional approach using retrospective evaluation of thyroid ultrasonographydata and post operative histopathology data to evaluate conformity relationship between TIRADS and post operativehistopathological result of thyroid nodule.There is comparable result (p=0.065) between TIRADS result and post operativehistopathological result of thyroidnodule. TIRADS resulted in 96.4% sensitivity; 83.0% specificity; 85.7% positive predictive value; dan 95.7% negativepredictive value.Conclusion: TIRADS can be implemented in evaluation, and reporting of thyroid ultrasonography result with gooddiagnostic value.
VEGF-C Serum Level as Predictor Lymph Node Metastasis in Advanced Stage Cervical Cancer PATIYUS AGUSTIANSYAH
Indonesian Journal of Cancer Vol 8, No 3 (2014): Jul - Sep 2014
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (822.343 KB) | DOI: 10.33371/ijoc.v8i3.357

Abstract

The aim of this study to identify correlation between VEGF-C and lymph node metastasis in advanced stage cervicalcancer in Dr. Hasan Sadikin General Hospital Bandung from April to August 2013.Cross sectional study from 30 patients diagnosed with advanced stage Cervical Cancer (IIB IVA). We performedtransperitoneal lymphadenectomy pelvic and para-aortic and measuring VEGF-C serum with ELISA priorchemoradiation.Results : 17/30 patients (56.7%) metastasis to pelvic lymph nodes and 4/30 pastients (13.3%) metastases to para-aorticlymph nodes. VEGF-C > 5333 pg/mL has a metastasis risk to pelvic lymph node 21.6 times with 94% sensitivity; 84.6%specificity; 88.9% positive predictive value; and 84.6% negative predictive value. Meanwhile VEGF-C > 8915.5 pg/mL hasa metastasis risk to para-aortic lymph node 15 times with 75% sensitivity, 100% specificity, 100% positive predictivevalue and 96.3% negative predictive value in advanced stage cervical cancer.Conclusion: a significant correlation between VEGF-C serum level with lymph node metastasis (pelvic and para-aortic)(p < 0.05)

Page 1 of 1 | Total Record : 6

 1 

Filter by Year

2014 2014


Reset
Filter By Issues
All Issue Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue